IGSC 20% infusion ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
65	Primary immunodeficiency	1

65. Primary immunodeficiency

---

Clinical trials : 500 /  Drugs : 614 - (DrugBank : 119) / Drug target genes : 92 - Drug target pathways : 217

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04842643 (ClinicalTrials.gov)	April 27, 2021	11/4/2021	An Extension Study of TAK-664 for Japanese People With Primary Immunodeficiency Disease	A Phase 3, Open-label, Non-controlled, Multi-dose, Extension Study to Evaluate the Long-term Safety and Tolerability of IGSC, 20% in Japanese Subjects With Primary Immunodeficiency Disease (PID)	Primary Immunodeficiency Disease	Biological: IGSC 20% infusion	Takeda	NULL	Active, not recruiting	2 Years	N/A	All	12	Phase 3	Japan